Tuesday, July 1, 2025 7/1/2025

Molecular biomarkers for kidney cancer prognosis using non-coding RNAs

Award Number: R01CA199694
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2016
PERIOD OF PERFORMANCE END DATE: 05/31/2022

Group Awards By:

View Award Description

Molecular biomarkers for kidney cancer prognosis using non-coding RNAs - DESCRIPTION (provided by applicant): The main goal of this project is to develop prognostic biomarkers based on long non-coding RNA analysis that can predict risk assessment of kidney cancer. The major problem or critical barrier in the field is that there are no biomarkers or methods to predict clinical outcome of kidney cancer. To address this problem, we will investigate whether long non-coding RNAs (lncRNAs) can be used as genetic biomarkers to predict which localized indolent kidney cancers are likely to progression and metastasize. Original Hypotheses: The proposed hypotheses are radically different and innovative. The first hypothesis is that the differential expression of oncogenic lncRNAs HOTAIR and MALAT1 and their binding miRNAs in different stages and grades of kidney cancer may serve as prognostic biomarkers. The second hypothesis is that suppression of oncogenic MALAT1 and HOTAIR by siRNAs or activation of their binding miRNAs will inhibit kidney cancer growth and progression using both in vitro and in vivo models. The third hypothesis is that the molecular mechanisms of oncogenic long non-coding RNAs HOTAIR and MALAT1 action is through binding to polycomb repressive complex 2, [PRC2 (EZH2 / SUZ12 / EED)] that in turn modulates histone modification complexes, activates epithelial-mesenchymal transition pathway genes (snail, slug, twist, vimentin, ZEB1 and ZEB2) and induces kidney cancer progression. To address these hypotheses, we have proposed the following specific aims. Specific Aim # 1. Investigate whether MALAT1, HOTAIR and their regulatory miRNAs are genetic biomarkers to help in the clinical assessment of kidney cancer. Specific Aim # 2. Investigate the functional significance of non-coding RNAs in suppression of kidney cancer growth and progression using both in vitro and in vivo models. Specific Aim # 3. Investigate the molecular mechanisms of action of MALAT1 and HOTAIR in kidney cancer growth and progression. Impact: This project has high impact because it will investigate the role of non-coding RNAs as genetic biomarkers for risk assessment of kidney cancer. We will investigate the functional significance of non-coding RNAs in kidney cancer using both in vitro and in vivo models. We will also investigate the molecular mechanisms of action of non-coding RNAs through binding to PCR2 that in turn modulates histone modification complexes, activates EMT genes and induces kidney cancer progression. The proposed concepts, methods and technology will advance the field of non-coding RNAs as genetic biomarkers and potential therapeutic targets for the management of kidney cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$294 )
2023	2020	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST # 151	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	5	11/30/2022	NON-COMPETING CONTINUATION	-$294
														Subtotal = -$294

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST 151 NC	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	5	4/26/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $350,674 )
2020	2020	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST 151 NC	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	5	5/12/2020	NON-COMPETING CONTINUATION	$350,674
														Subtotal = $350,674

Issue Date FY: 2019 ( Subtotal = $340,153 )
2019	2019	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST 151 NC	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	4	5/31/2019	NON-COMPETING CONTINUATION	$340,153
														Subtotal = $340,153

Issue Date FY: 2018 ( Subtotal = $350,674 )
2018	2018	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST 151 NC	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	3	5/14/2018	NON-COMPETING CONTINUATION	$350,674
														Subtotal = $350,674

Issue Date FY: 2017 ( Subtotal = $350,674 )
2017	2017	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION, INC.	4150 CLEMENT ST 151 NC	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	2	5/19/2017	NON-COMPETING CONTINUATION	$350,674
														Subtotal = $350,674

Issue Date FY: 2016 ( Subtotal = $350,674 )
2016	2016	NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH & EDUCATION	4150 CLEMENT STREET	SAN FRANCISCO	CA	94121	SAN FRANCISCO	USA	Cancer Biology Research	000	1	5/6/2016	NEW	$350,674
														Subtotal = $350,674

Grand Total All Awards = $1,742,555

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Molecular biomarkers for kidney cancer prognosis using non-coding RNAs

Award Number: R01CA199694

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2016

PERIOD OF PERFORMANCE END DATE: 05/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer